TRDA Stock Overview
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Entrada Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.43 |
| 52 Week High | US$18.44 |
| 52 Week Low | US$10.62 |
| Beta | -0.50 |
| 1 Month Change | -7.10% |
| 3 Month Change | -16.58% |
| 1 Year Change | -11.97% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -48.10% |
Recent News & Updates
Recent updates
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
Mar 19
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Nov 09Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
May 26Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 14Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Aug 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31Shareholder Returns
| TRDA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.7% | 1.0% | 1.2% |
| 1Y | -12.0% | 0.7% | 24.9% |
Return vs Industry: TRDA underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: TRDA underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| TRDA volatility | |
|---|---|
| TRDA Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRDA's share price has been volatile over the past 3 months.
Volatility Over Time: TRDA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 159 | Dipal Doshi | www.entradatx.com |
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Entrada Therapeutics, Inc. Fundamentals Summary
| TRDA fundamental statistics | |
|---|---|
| Market cap | US$417.76m |
| Earnings (TTM) | -US$6.68m |
| Revenue (TTM) | US$129.01m |
3.1x
P/S Ratio-60.3x
P/E RatioIs TRDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRDA income statement (TTM) | |
|---|---|
| Revenue | US$129.01m |
| Cost of Revenue | US$99.88m |
| Gross Profit | US$29.13m |
| Other Expenses | US$35.81m |
| Earnings | -US$6.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 22.58% |
| Net Profit Margin | -5.18% |
| Debt/Equity Ratio | 0% |
How did TRDA perform over the long term?
See historical performance and comparison